EU/3/19/2169

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2169 was granted by the European Commission to Pharma Gateway AB, Sweden, for reldesemtiv for the treatment of spinal muscular atrophy.

Key facts

Active substance
Reldesemtiv
Disease / condition
Treatment of spinal muscular atrophy
Date of first decision
28/06/2019
Outcome
Positive
EU designation number
EU/3/19/2169

Sponsor's contact details

Pharma Gateway AB
Johanneslundsvägen 2
194 61 Upplands Väsby
Sweden
Tel. +46 8590 77800
E-mail: info@pharmagateway.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating